跳至主要内容
临床试验/NCT01008774
NCT01008774已完成不适用

A Comparison of Different Scalp Cooling Systems for the Prevention of Chemotherapy Induced Alopecia

Sanofi1 个研究点 分布在 1 个国家目标入组 239 人开始时间: 2009年7月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
Sanofi
入组人数
239
试验地点
1
主要终点
Grade III or IV alopecia according to the WHO criteria

研究概览

简要总结

Primary objective:

  • Rate of complete chemotherapy induced alopecia (WHO grade III or IV, physician grading)

Secondary objective:

  • Compliance to scalp cooling procedure
  • Received number of cycles of chemotherapy in each subgroup
  • Patient perception of scalp cooling procedure
  • Side effects of scalp cooling systems

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Any solid tumor malignancy receiving docetaxel (Taxotere®) 1st line chemotherapy treatment with the exception of regimen containing concomitant anthracycline treatment; sequential anthracycline/docetaxel treatment is permitted.
  • •Performance Status ECOG <= 2
  • •Absence of alopecia at inclusion

排除标准

  • •Chemotherapy regimen including concomitant anthracycline treatment
  • •Raynaud's disease or phenomenon
  • •Cold agglutinin disease
  • •Cryoglobulinemia
  • •Cryofibrinogenemia
  • •Scalp metastasis
  • •Pregnancy or Lactation
  • •Preexisting alopecia of any grade; notably androgenetic alopecia

研究组 & 干预措施

A

Experimental

干预措施: Paxman Cooling Machine (Device)

B

Active Comparator

干预措施: Cold Caps (Device)

C

No Intervention

结局指标

主要结局

Grade III or IV alopecia according to the WHO criteria

时间窗: D1 of each cycle and D+21 after last cycle of chemotherapy

次要结局

  • Side effects of scalp cooling systems(D1 of each cycle and D+21 after last cycle of chemotherapy)
  • Compliance to scalp cooling procedure(D1 of each cycle and D+21 after last cycle of chemotherapy)

研究者

发起方
Sanofi
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验